hu.MAP 2.0: Complex View
Human Protein Complex Map
Search for a protein
Complex: HuMAP2_01070
Confidence: Medium
Proteins| Genename | Protein Name | Links |
|---|---|---|
| MAP2K2 | Dual specificity mitogen-activated protein kinase kinase 2 (MAP kinase kinase 2) (MAPKK 2) (EC 2.7.12.2) (ERK activator kinase 2) (MAPK/ERK kinase 2) (MEK 2) | UniProt NCBI |
| ARAF | Serine/threonine-protein kinase A-Raf (EC 2.7.11.1) (Proto-oncogene A-Raf) (Proto-oncogene A-Raf-1) (Proto-oncogene Pks) | UniProt NCBI |
| MAP2K1 | Dual specificity mitogen-activated protein kinase kinase 1 (MAP kinase kinase 1) (MAPKK 1) (MKK1) (EC 2.7.12.2) (ERK activator kinase 1) (MAPK/ERK kinase 1) (MEK 1) | UniProt NCBI |
| BRAF | Serine/threonine-protein kinase B-raf (EC 2.7.11.1) (Proto-oncogene B-Raf) (p94) (v-Raf murine sarcoma viral oncogene homolog B1) | UniProt NCBI |
| RAB3GAP1 | Rab3 GTPase-activating protein catalytic subunit (RAB3 GTPase-activating protein 130 kDa subunit) (Rab3-GAP p130) (Rab3-GAP) | UniProt NCBI |
| KRAS | GTPase KRas (K-Ras 2) (Ki-Ras) (c-K-ras) (c-Ki-ras) [Cleaved into: GTPase KRas, N-terminally processed] | UniProt NCBI |
| RAF1 | RAF proto-oncogene serine/threonine-protein kinase (EC 2.7.11.1) (Proto-oncogene c-RAF) (cRaf) (Raf-1) | UniProt NCBI |
| KSR1 | Kinase suppressor of Ras 1 | UniProt NCBI |
| CIRBP-AS1 | NCBI |
Enrichments
| Term ID | Corrected Pval | Fraction Complex Coverage | Proteins | Term Name |
|---|---|---|---|---|
| REAC:R-HSA-5673000 | 6.86363459073e-17 | 0.875 | MAP2K1 BRAF KRAS KSR1 MAP2K2 ARAF RAF1 | RAF activation |
| REAC:R-HSA-6802948 | 3.6694358886e-16 | 0.875 | MAP2K1 BRAF KRAS KSR1 MAP2K2 ARAF RAF1 | Signaling by high-kinase activity BRAF mutants |
| REAC:R-HSA-5675221 | 4.52537114238e-16 | 0.875 | MAP2K1 BRAF KRAS KSR1 MAP2K2 ARAF RAF1 | Negative regulation of MAPK pathway |
| REAC:R-HSA-5674135 | 8.19332280117e-16 | 0.875 | MAP2K1 BRAF KRAS KSR1 MAP2K2 ARAF RAF1 | MAP2K and MAPK activation |
| REAC:R-HSA-6802955 | 1.68368500273e-15 | 0.875 | MAP2K1 BRAF KRAS KSR1 MAP2K2 ARAF RAF1 | Paradoxical activation of RAF signaling by kinase inactive BRAF |
| REAC:R-HSA-6802946 | 1.68368500273e-15 | 0.875 | MAP2K1 BRAF KRAS KSR1 MAP2K2 ARAF RAF1 | Signaling by moderate kinase activity BRAF mutants |
| REAC:R-HSA-6802949 | 1.01825171323e-14 | 0.875 | MAP2K1 BRAF KRAS KSR1 MAP2K2 ARAF RAF1 | Signaling by RAS mutants |
| REAC:R-HSA-6802952 | 2.42817637115e-14 | 0.875 | MAP2K1 BRAF KRAS KSR1 MAP2K2 ARAF RAF1 | Signaling by BRAF and RAF fusions |
| WP:WP422 | 1.03298037532e-13 | 0.75 | MAP2K1 BRAF KRAS MAP2K2 ARAF RAF1 | MAPK Cascade |
| REAC:R-HSA-6802957 | 1.15844381895e-13 | 0.875 | MAP2K1 BRAF KRAS KSR1 MAP2K2 ARAF RAF1 | Oncogenic MAPK signaling |
| WP:WP2828 | 1.81599221358e-13 | 0.75 | MAP2K1 BRAF KRAS MAP2K2 ARAF RAF1 | Bladder Cancer |
| KEGG:05219 | 2.05886335085e-13 | 0.75 | MAP2K1 BRAF KRAS MAP2K2 ARAF RAF1 | Bladder cancer |
| KEGG:04730 | 2.02939801105e-12 | 0.75 | MAP2K1 BRAF KRAS MAP2K2 ARAF RAF1 | Long-term depression |
| KEGG:05213 | 3.2063319043e-12 | 0.75 | MAP2K1 BRAF KRAS MAP2K2 ARAF RAF1 | Endometrial cancer |
| WP:WP4205 | 3.37508621506e-12 | 0.75 | MAP2K1 BRAF KRAS MAP2K2 ARAF RAF1 | MET in type 1 papillary renal cell carcinoma |
| KEGG:05221 | 4.42197505304e-12 | 0.75 | MAP2K1 BRAF KRAS MAP2K2 ARAF RAF1 | Acute myeloid leukemia |
| HP:0001003 | 4.77501962453e-12 | 0.625 | MAP2K1 KRAS BRAF RAF1 MAP2K2 | Multiple lentigines |
| KEGG:04720 | 5.42858657165e-12 | 0.75 | MAP2K1 BRAF KRAS MAP2K2 ARAF RAF1 | Long-term potentiation |
| KEGG:05218 | 5.42858657165e-12 | 0.75 | MAP2K1 BRAF KRAS MAP2K2 ARAF RAF1 | Melanoma |
| WP:WP4155 | 5.71430165436e-12 | 0.75 | MAP2K1 BRAF KRAS MAP2K2 ARAF RAF1 | Endometrial cancer |
| KEGG:05211 | 5.9993236746e-12 | 0.75 | MAP2K1 BRAF KRAS MAP2K2 ARAF RAF1 | Renal cell carcinoma |
| KEGG:05223 | 6.61917865156e-12 | 0.75 | MAP2K1 BRAF KRAS MAP2K2 ARAF RAF1 | Non-small cell lung cancer |
| CORUM:5877 | 7.90426989013e-12 | 0.5 | MAP2K1 KSR1 BRAF RAF1 | MAP2K1-BRAF-RAF1-YWHAE-KSR1 complex |
| KEGG:05214 | 9.65872077115e-12 | 0.75 | MAP2K1 BRAF KRAS MAP2K2 ARAF RAF1 | Glioma |
| WP:WP4255 | 1.21764934521e-11 | 0.75 | MAP2K1 BRAF KRAS MAP2K2 ARAF RAF1 | Non-small cell lung cancer |
| KEGG:05220 | 1.63361413008e-11 | 0.75 | MAP2K1 BRAF KRAS MAP2K2 ARAF RAF1 | Chronic myeloid leukemia |
| KEGG:01521 | 1.63361413008e-11 | 0.75 | MAP2K1 BRAF KRAS MAP2K2 ARAF RAF1 | EGFR tyrosine kinase inhibitor resistance |
| KEGG:04012 | 2.4497675625e-11 | 0.75 | MAP2K1 BRAF KRAS MAP2K2 ARAF RAF1 | ErbB signaling pathway |
| KEGG:05210 | 3.08500949088e-11 | 0.75 | MAP2K1 BRAF KRAS MAP2K2 ARAF RAF1 | Colorectal cancer |
| WP:WP2261 | 3.24737841145e-11 | 0.75 | MAP2K1 BRAF KRAS MAP2K2 ARAF RAF1 | Signaling Pathways in Glioblastoma |
| WP:WP4263 | 3.50001609338e-11 | 0.75 | MAP2K1 BRAF KRAS MAP2K2 ARAF RAF1 | Pancreatic adenocarcinoma pathway |
| WP:WP673 | 4.05458211511e-11 | 0.75 | MAP2K1 BRAF KRAS MAP2K2 ARAF RAF1 | ErbB Signaling Pathway |
| KEGG:01522 | 5.48031049144e-11 | 0.75 | MAP2K1 BRAF KRAS MAP2K2 ARAF RAF1 | Endocrine resistance |
| KEGG:05215 | 5.48031049144e-11 | 0.75 | MAP2K1 BRAF KRAS MAP2K2 ARAF RAF1 | Prostate cancer |
| REAC:R-HSA-5673001 | 8.00960205803e-11 | 0.875 | MAP2K1 BRAF KRAS KSR1 MAP2K2 ARAF RAF1 | RAF/MAP kinase cascade |
| REAC:R-HSA-5674499 | 9.07954978468e-11 | 0.5 | MAP2K1 BRAF RAF1 MAP2K2 | Negative feedback regulation of MAPK pathway |
| REAC:R-HSA-5684996 | 9.59509317622e-11 | 0.875 | MAP2K1 BRAF KRAS KSR1 MAP2K2 ARAF RAF1 | MAPK1/MAPK3 signaling |
| KEGG:04650 | 9.85273291121e-11 | 0.75 | MAP2K1 BRAF KRAS MAP2K2 ARAF RAF1 | Natural killer cell mediated cytotoxicity |
| REAC:R-HSA-9607240 | 1.45347598141e-10 | 0.875 | MAP2K1 BRAF KRAS KSR1 MAP2K2 ARAF RAF1 | FLT3 Signaling |
| HP:0030141 | 1.72886225569e-10 | 0.75 | MAP2K1 RAB3GAP1 BRAF KRAS MAP2K2 RAF1 | Abnormality of the posterior hairline |
| HP:0002162 | 1.72886225569e-10 | 0.75 | MAP2K1 RAB3GAP1 BRAF KRAS MAP2K2 RAF1 | Low posterior hairline |
| KEGG:04068 | 2.34093897083e-10 | 0.75 | MAP2K1 BRAF KRAS MAP2K2 ARAF RAF1 | FoxO signaling pathway |
| REAC:R-HSA-449836 | 2.43953152026e-10 | 0.875 | MAP2K1 BRAF KRAS KSR1 MAP2K2 ARAF RAF1 | Other interleukin signaling |
| WP:WP4549 | 2.59948617781e-10 | 0.75 | MAP2K1 BRAF KRAS MAP2K2 ARAF RAF1 | Fragile X Syndrome |
| REAC:R-HSA-5683057 | 3.21246294675e-10 | 0.875 | MAP2K1 BRAF KRAS KSR1 MAP2K2 ARAF RAF1 | MAPK family signaling cascades |
| HP:0000391 | 3.95659981351e-10 | 0.625 | MAP2K1 KRAS BRAF RAF1 MAP2K2 | Thickened helices |
| KEGG:04910 | 4.1120296105e-10 | 0.75 | MAP2K1 BRAF KRAS MAP2K2 ARAF RAF1 | Insulin signaling pathway |
| KEGG:05224 | 5.22478617087e-10 | 0.75 | MAP2K1 BRAF KRAS MAP2K2 ARAF RAF1 | Breast cancer |
| KEGG:05226 | 5.47494098175e-10 | 0.75 | MAP2K1 BRAF KRAS MAP2K2 ARAF RAF1 | Gastric cancer |
| KEGG:05160 | 6.88039447645e-10 | 0.75 | MAP2K1 BRAF KRAS MAP2K2 ARAF RAF1 | Hepatitis C |
| WP:WP4262 | 8.27286949572e-10 | 0.75 | MAP2K1 BRAF KRAS MAP2K2 ARAF RAF1 | Breast cancer pathway |
| HP:0007392 | 8.56582796195e-10 | 0.625 | MAP2K1 KRAS BRAF RAF1 MAP2K2 | Excessive wrinkled skin |
| WP:WP4666 | 1.07019742075e-09 | 0.75 | MAP2K1 BRAF KRAS MAP2K2 ARAF RAF1 | Hepatitis B infection |
| HP:0002967 | 1.425872625e-09 | 0.625 | MAP2K1 KRAS BRAF RAF1 MAP2K2 | Cubitus valgus |
| HP:0007495 | 1.43416239259e-09 | 0.75 | MAP2K1 RAB3GAP1 BRAF KRAS MAP2K2 RAF1 | Prematurely aged appearance |
| KEGG:05161 | 1.52558688868e-09 | 0.75 | MAP2K1 BRAF KRAS MAP2K2 ARAF RAF1 | Hepatitis B |
| KEGG:05225 | 1.78119075942e-09 | 0.75 | MAP2K1 BRAF KRAS MAP2K2 ARAF RAF1 | Hepatocellular carcinoma |
| REAC:R-HSA-5663202 | 3.97199082443e-09 | 0.875 | MAP2K1 BRAF KRAS KSR1 MAP2K2 ARAF RAF1 | Diseases of signal transduction |
| HP:0100678 | 4.49619611084e-09 | 0.625 | MAP2K1 KRAS BRAF RAF1 MAP2K2 | Premature skin wrinkling |
| CORUM:5921 | 4.70911134935e-09 | 0.375 | MAP2K1 BRAF KSR1 | KSR1-BRAF-MEK complex |
| CORUM:5920 | 4.70911134935e-09 | 0.375 | MAP2K1 RAF1 KSR1 | KSR1-RAF1-MEK complex |
| KEGG:04810 | 4.76686210166e-09 | 0.75 | MAP2K1 BRAF KRAS MAP2K2 ARAF RAF1 | Regulation of actin cytoskeleton |
| KEGG:05205 | 4.9234385807e-09 | 0.75 | MAP2K1 BRAF KRAS MAP2K2 ARAF RAF1 | Proteoglycans in cancer |
| WP:WP4301 | 5.27310139965e-09 | 0.5 | ARAF BRAF RAF1 KRAS | Inhibition of exosome biogenesis and secretion by Manumycin A in CRPC cells |
| KEGG:05212 | 5.67972393584e-09 | 0.625 | ARAF MAP2K1 BRAF RAF1 KRAS | Pancreatic cancer |
| WP:WP4216 | 5.97865677457e-09 | 0.625 | ARAF MAP2K1 BRAF RAF1 KRAS | Chromosomal and microsatellite instability in colorectal cancer |
| HP:0000974 | 6.51248187942e-09 | 0.625 | MAP2K1 KRAS BRAF RAF1 MAP2K2 | Hyperextensible skin |
| WP:WP732 | 8.34548656562e-09 | 0.5 | MAP2K1 MAP2K2 RAF1 KRAS | Serotonin Receptor 2 and ELK-SRF/GATA4 signaling |
| KEGG:04914 | 1.1158182313e-08 | 0.625 | ARAF MAP2K1 BRAF RAF1 KRAS | Progesterone-mediated oocyte maturation |
| HP:0009553 | 1.17329529464e-08 | 0.75 | MAP2K1 RAB3GAP1 BRAF KRAS MAP2K2 RAF1 | Abnormality of the hairline |
| WP:WP382 | 1.30524034704e-08 | 0.75 | MAP2K1 BRAF KRAS MAP2K2 ARAF RAF1 | MAPK Signaling Pathway |
| HP:0001004 | 1.71826397599e-08 | 0.625 | MAP2K1 KRAS BRAF RAF1 MAP2K2 | Lymphedema |
| CORUM:5872 | 1.8831701816e-08 | 0.375 | MAP2K1 BRAF MAP2K2 | BRAF-MAP2K1-MAP2K2-YWHAE complex |
| HP:0011361 | 1.92909278973e-08 | 0.75 | MAP2K1 RAB3GAP1 BRAF KRAS MAP2K2 RAF1 | Congenital abnormal hair pattern |
| WP:WP185 | 2.3776514506e-08 | 0.625 | ARAF MAP2K1 BRAF RAF1 MAP2K2 | Integrin-mediated Cell Adhesion |
| KEGG:04726 | 2.51735345269e-08 | 0.625 | ARAF MAP2K1 BRAF RAF1 KRAS | Serotonergic synapse |
| WP:WP3931 | 3.10425670037e-08 | 0.625 | ARAF MAP2K1 BRAF RAF1 MAP2K2 | ESC Pluripotency Pathways |
| KEGG:04270 | 3.10538381921e-08 | 0.625 | ARAF MAP2K1 BRAF RAF1 MAP2K2 | Vascular smooth muscle contraction |
| KEGG:04010 | 3.18186419016e-08 | 0.75 | MAP2K1 BRAF KRAS MAP2K2 ARAF RAF1 | MAPK signaling pathway |
| WP:WP2643 | 3.52074324379e-08 | 0.5 | MAP2K1 MAP2K2 RAF1 KRAS | Nanoparticle-mediated activation of receptor signaling |
| HP:0010720 | 3.53055562702e-08 | 0.75 | MAP2K1 RAB3GAP1 BRAF KRAS MAP2K2 RAF1 | Abnormal hair pattern |
| HP:0001034 | 3.86873544276e-08 | 0.625 | MAP2K1 KRAS BRAF RAF1 MAP2K2 | Hypermelanotic macule |
| KEGG:04722 | 4.60946484651e-08 | 0.625 | MAP2K1 KRAS BRAF RAF1 MAP2K2 | Neurotrophin signaling pathway |
| HP:0007477 | 5.3530203572e-08 | 0.75 | MAP2K1 RAB3GAP1 BRAF KRAS MAP2K2 RAF1 | Abnormal dermatoglyphics |
| WP:WP3981 | 7.02876103384e-08 | 0.5 | MAP2K1 MAP2K2 RAF1 KRAS | miRNA regulation of prostate cancer signaling pathways |
| REAC:R-HSA-449147 | 7.30033270747e-08 | 0.875 | MAP2K1 BRAF KRAS KSR1 MAP2K2 ARAF RAF1 | Signaling by Interleukins |
| HP:0000368 | 8.40743114947e-08 | 0.75 | MAP2K1 RAB3GAP1 BRAF KRAS MAP2K2 RAF1 | Low-set, posteriorly rotated ears |
| HP:0006191 | 8.68117300962e-08 | 0.5 | MAP2K1 KRAS BRAF MAP2K2 | Deep palmar crease |
| KEGG:05216 | 1.07679440717e-07 | 0.5 | MAP2K1 KRAS BRAF MAP2K2 | Thyroid cancer |
| WP:WP2636 | 1.26654427598e-07 | 0.5 | MAP2K1 MAP2K2 RAF1 ARAF | Common Pathways Underlying Drug Addiction |
| WP:WP127 | 1.26654427598e-07 | 0.5 | MAP2K1 MAP2K2 RAF1 KRAS | IL-5 Signaling Pathway |
| HP:0002212 | 1.3398987248e-07 | 0.5 | MAP2K1 BRAF RAF1 KRAS | Curly hair |
| WP:WP51 | 1.4058255125e-07 | 0.625 | MAP2K1 KRAS BRAF RAF1 MAP2K2 | Regulation of Actin Cytoskeleton |
| HP:0000465 | 1.43289705917e-07 | 0.625 | MAP2K1 KRAS BRAF RAF1 MAP2K2 | Webbed neck |
| HP:0001642 | 1.43289705917e-07 | 0.625 | MAP2K1 KRAS BRAF RAF1 MAP2K2 | Pulmonic stenosis |
| HP:0100037 | 1.79264925745e-07 | 0.75 | MAP2K1 RAB3GAP1 BRAF KRAS MAP2K2 RAF1 | Abnormality of the scalp hair |
| HP:0001965 | 2.05211747543e-07 | 0.75 | MAP2K1 RAB3GAP1 BRAF KRAS MAP2K2 RAF1 | Abnormality of the scalp |
| KEGG:04150 | 2.07261907918e-07 | 0.625 | MAP2K1 KRAS BRAF RAF1 MAP2K2 | mTOR signaling pathway |
| HP:0001048 | 2.37737319435e-07 | 0.5 | MAP2K1 KRAS BRAF MAP2K2 | Cavernous hemangioma |
| HP:0000957 | 2.76674552476e-07 | 0.625 | MAP2K1 KRAS BRAF RAF1 MAP2K2 | Cafe-au-lait spot |
| HP:0008391 | 2.82959737375e-07 | 0.5 | MAP2K1 KRAS BRAF MAP2K2 | Dystrophic fingernails |
| WP:WP4223 | 3.1624079989e-07 | 0.625 | MAP2K1 KSR1 MAP2K2 RAF1 KRAS | Ras Signaling |
| HP:0012733 | 3.26404487513e-07 | 0.625 | MAP2K1 KRAS BRAF RAF1 MAP2K2 | Macule |
| HP:0011039 | 3.44479946157e-07 | 0.625 | MAP2K1 KRAS BRAF RAF1 MAP2K2 | Abnormality of the helix |
| WP:WP437 | 3.71094375286e-07 | 0.625 | MAP2K1 KRAS BRAF RAF1 MAP2K2 | EGF/EGFR Signaling Pathway |
| HP:0031654 | 4.03553371048e-07 | 0.625 | MAP2K1 KRAS BRAF RAF1 MAP2K2 | Abnormal pulmonary valve physiology |
| KEGG:05034 | 4.24332989862e-07 | 0.625 | ARAF MAP2K1 BRAF RAF1 KRAS | Alcoholism |
| HP:0010669 | 4.57696621693e-07 | 0.5 | MAP2K1 KRAS BRAF MAP2K2 | Hypoplasia of the zygomatic bone |
| KEGG:04929 | 5.13729900054e-07 | 0.5 | MAP2K1 MAP2K2 RAF1 KRAS | GnRH secretion |
| KEGG:04015 | 5.22347635873e-07 | 0.625 | MAP2K1 KRAS BRAF RAF1 MAP2K2 | Rap1 signaling pathway |
| HP:0002217 | 5.3081385092e-07 | 0.5 | MAP2K1 KRAS BRAF MAP2K2 | Slow-growing hair |
| HP:0011363 | 5.3081385092e-07 | 0.5 | MAP2K1 KRAS BRAF MAP2K2 | Abnormality of hair growth rate |
| KEGG:04664 | 5.53903096274e-07 | 0.5 | MAP2K1 MAP2K2 RAF1 KRAS | Fc epsilon RI signaling pathway |
| KEGG:04370 | 5.53903096274e-07 | 0.5 | MAP2K1 MAP2K2 RAF1 KRAS | VEGF signaling pathway |
| REAC:R-HSA-1280215 | 6.05667384357e-07 | 0.875 | MAP2K1 BRAF KRAS KSR1 MAP2K2 ARAF RAF1 | Cytokine Signaling in Immune system |
| HP:0040170 | 6.12345738323e-07 | 0.5 | MAP2K1 KRAS BRAF MAP2K2 | Abnormality of hair growth |
| HP:0011356 | 6.8512667613e-07 | 0.75 | MAP2K1 RAB3GAP1 BRAF KRAS MAP2K2 RAF1 | Regional abnormality of skin |
| HP:0008067 | 6.92952226299e-07 | 0.625 | MAP2K1 KRAS BRAF RAF1 MAP2K2 | Abnormally lax or hyperextensible skin |
| KEGG:04014 | 7.12090400868e-07 | 0.625 | MAP2K1 KSR1 MAP2K2 RAF1 KRAS | Ras signaling pathway |
| KEGG:04917 | 9.04623461234e-07 | 0.5 | MAP2K1 MAP2K2 RAF1 KRAS | Prolactin signaling pathway |
| HP:0007400 | 9.50206180813e-07 | 0.625 | MAP2K1 KRAS BRAF RAF1 MAP2K2 | Irregular hyperpigmentation |
| HP:0000958 | 1.08146203803e-06 | 0.625 | MAP2K1 KRAS BRAF RAF1 MAP2K2 | Dry skin |
| HP:0002997 | 1.08146203803e-06 | 0.625 | MAP2K1 KRAS BRAF RAF1 MAP2K2 | Abnormality of the ulna |
| WP:WP2374 | 1.08411237168e-06 | 0.5 | MAP2K1 MAP2K2 RAF1 KRAS | Oncostatin M Signaling Pathway |
| HP:0000358 | 1.10921036617e-06 | 0.75 | MAP2K1 RAB3GAP1 BRAF KRAS MAP2K2 RAF1 | Posteriorly rotated ears |
| KEGG:05200 | 1.14514560109e-06 | 0.75 | MAP2K1 BRAF KRAS MAP2K2 ARAF RAF1 | Pathways in cancer |
| HP:0000476 | 1.16868964563e-06 | 0.5 | MAP2K1 BRAF RAF1 KRAS | Cystic hygroma |
| KEGG:05230 | 1.24161539819e-06 | 0.5 | MAP2K1 MAP2K2 RAF1 KRAS | Central carbon metabolism in cancer |
| KEGG:04662 | 1.24161539819e-06 | 0.5 | MAP2K1 MAP2K2 RAF1 KRAS | B cell receptor signaling pathway |
| HP:0007440 | 1.47350813613e-06 | 0.5 | MAP2K1 KRAS BRAF MAP2K2 | Generalized hyperpigmentation |
| HP:0002692 | 1.47350813613e-06 | 0.5 | MAP2K1 KRAS BRAF MAP2K2 | Hypoplastic facial bones |
| HP:0002299 | 1.64650755877e-06 | 0.5 | MAP2K1 KRAS BRAF MAP2K2 | Brittle hair |
| HP:0000982 | 1.82757316625e-06 | 0.625 | MAP2K1 KRAS BRAF RAF1 MAP2K2 | Palmoplantar keratoderma |
| HP:0008872 | 2.15771512898e-06 | 0.75 | MAP2K1 RAB3GAP1 BRAF KRAS MAP2K2 RAF1 | Feeding difficulties in infancy |
| HP:0010719 | 2.37279174366e-06 | 0.625 | MAP2K1 KRAS BRAF RAF1 MAP2K2 | Abnormality of hair texture |
| KEGG:05235 | 2.55481824631e-06 | 0.5 | MAP2K1 MAP2K2 RAF1 KRAS | PD-L1 expression and PD-1 checkpoint pathway in cancer |
| KEGG:04912 | 2.68695643145e-06 | 0.5 | MAP2K1 MAP2K2 RAF1 KRAS | GnRH signaling pathway |
| WP:WP734 | 2.8732374251e-06 | 0.375 | MAP2K1 BRAF MAP2K2 | Serotonin Receptor 4/6/7 and NR3C Signaling |
| HP:0000126 | 2.9370121183e-06 | 0.625 | RAB3GAP1 MAP2K1 KRAS BRAF MAP2K2 | Hydronephrosis |
| HP:0010946 | 2.9370121183e-06 | 0.625 | RAB3GAP1 MAP2K1 KRAS BRAF MAP2K2 | Dilatation of the renal pelvis |
| HP:0009891 | 3.02413459246e-06 | 0.5 | MAP2K1 KRAS BRAF MAP2K2 | Underdeveloped supraorbital ridges |
| KEGG:04540 | 3.11414702477e-06 | 0.5 | MAP2K1 MAP2K2 RAF1 KRAS | Gap junction |
| HP:0010944 | 3.14717959402e-06 | 0.625 | RAB3GAP1 MAP2K1 KRAS BRAF MAP2K2 | Abnormal renal pelvis morphology |
| HP:0005280 | 3.32797553621e-06 | 0.75 | MAP2K1 RAB3GAP1 BRAF KRAS MAP2K2 RAF1 | Depressed nasal bridge |
| HP:0010647 | 3.36917849524e-06 | 0.625 | MAP2K1 KRAS BRAF RAF1 MAP2K2 | Abnormal elasticity of skin |
| KEGG:05231 | 3.93644983247e-06 | 0.5 | MAP2K1 MAP2K2 RAF1 KRAS | Choline metabolism in cancer |
| KEGG:04916 | 3.93644983247e-06 | 0.5 | MAP2K1 MAP2K2 RAF1 KRAS | Melanogenesis |
| WP:WP23 | 3.95825481308e-06 | 0.5 | MAP2K1 BRAF RAF1 MAP2K2 | B Cell Receptor Signaling Pathway |
| KEGG:04660 | 4.11865164605e-06 | 0.5 | MAP2K1 MAP2K2 RAF1 KRAS | T cell receptor signaling pathway |
| WP:WP3879 | 4.18460792347e-06 | 0.375 | MAP2K1 MAP2K2 RAF1 | 4-hydroxytamoxifen, Dexamethasone, and Retinoic Acids Regulation of p27 Expression |
| HP:0100625 | 4.71489690537e-06 | 0.5 | MAP2K1 BRAF RAF1 KRAS | Enlarged thorax |
| HP:0000400 | 5.29729649863e-06 | 0.625 | RAB3GAP1 MAP2K1 KRAS BRAF MAP2K2 | Macrotia |
| GO:0031401 | 5.35155805489e-06 | 1.0 | MAP2K1 RAB3GAP1 BRAF KRAS RAF1 KSR1 ARAF MAP2K2 | positive regulation of protein modification process |
| KEGG:04928 | 5.57646390748e-06 | 0.5 | MAP2K1 BRAF RAF1 ARAF | Parathyroid hormone synthesis, secretion and action |
| REAC:R-HSA-1643685 | 5.59548960867e-06 | 0.875 | MAP2K1 BRAF KRAS KSR1 MAP2K2 ARAF RAF1 | Disease |
| HP:0410031 | 6.02057761541e-06 | 0.5 | MAP2K1 KRAS BRAF MAP2K2 | Submucous cleft of soft and hard palate |
| HP:0000176 | 6.02057761541e-06 | 0.5 | MAP2K1 KRAS BRAF MAP2K2 | Submucous cleft hard palate |
| HP:0007565 | 6.51065067465e-06 | 0.5 | MAP2K1 KRAS BRAF MAP2K2 | Multiple cafe-au-lait spots |
| HP:0040072 | 6.74182898271e-06 | 0.625 | MAP2K1 KRAS BRAF RAF1 MAP2K2 | Abnormality of forearm bone |
| HP:0002973 | 7.14791501721e-06 | 0.625 | MAP2K1 KRAS BRAF RAF1 MAP2K2 | Abnormality of the forearm |
| HP:0001582 | 7.57972658059e-06 | 0.5 | MAP2K1 KRAS BRAF MAP2K2 | Redundant skin |
| HP:0000464 | 7.93436701834e-06 | 0.75 | MAP2K1 RAB3GAP1 BRAF KRAS MAP2K2 RAF1 | Abnormality of the neck |
| HP:0000309 | 8.04953086472e-06 | 0.75 | MAP2K1 RAB3GAP1 BRAF KRAS MAP2K2 RAF1 | Abnormality of the midface |
| HP:0000953 | 8.72548193641e-06 | 0.625 | MAP2K1 KRAS BRAF RAF1 MAP2K2 | Hyperpigmentation of the skin |
| HP:0000637 | 8.77505947104e-06 | 0.5 | MAP2K1 KRAS BRAF MAP2K2 | Long palpebral fissure |
| KEGG:04071 | 8.93056698432e-06 | 0.5 | MAP2K1 MAP2K2 RAF1 KRAS | Sphingolipid signaling pathway |
| HP:0000348 | 9.74439495925e-06 | 0.625 | MAP2K1 KRAS BRAF RAF1 MAP2K2 | High forehead |
| KEGG:04919 | 1.03270436652e-05 | 0.5 | MAP2K1 MAP2K2 RAF1 KRAS | Thyroid hormone signaling pathway |
| HP:0009811 | 1.05690951671e-05 | 0.625 | MAP2K1 KRAS BRAF RAF1 MAP2K2 | Abnormality of the elbow |
| HP:0004422 | 1.08257028835e-05 | 0.5 | MAP2K1 KRAS BRAF MAP2K2 | Biparietal narrowing |
| CORUM:5923 | 1.16880143691e-05 | 0.25 | BRAF RAF1 | RAF1-BRAF complex, RAS stimulated |
| HP:0002213 | 1.23790578906e-05 | 0.5 | MAP2K1 KRAS BRAF MAP2K2 | Fine hair |
| HP:0010668 | 1.30431255222e-05 | 0.625 | RAB3GAP1 MAP2K1 KRAS BRAF MAP2K2 | Abnormality of the zygomatic bone |
| KEGG:04926 | 1.31553709064e-05 | 0.5 | MAP2K1 MAP2K2 RAF1 KRAS | Relaxin signaling pathway |
| WP:WP581 | 1.33064530871e-05 | 0.375 | MAP2K1 MAP2K2 RAF1 | EPO Receptor Signaling |
| KEGG:04915 | 1.40602393667e-05 | 0.5 | MAP2K1 MAP2K2 RAF1 KRAS | Estrogen signaling pathway |
| KEGG:04550 | 1.45297118091e-05 | 0.5 | MAP2K1 MAP2K2 RAF1 KRAS | Signaling pathways regulating pluripotency of stem cells |
| KEGG:04371 | 1.50107907507e-05 | 0.5 | MAP2K1 MAP2K2 RAF1 KRAS | Apelin signaling pathway |
| HP:0200102 | 1.50143856476e-05 | 0.5 | MAP2K1 KRAS BRAF MAP2K2 | Sparse or absent eyelashes |
| HP:0000218 | 1.52718043824e-05 | 0.75 | MAP2K1 RAB3GAP1 BRAF KRAS MAP2K2 RAF1 | High palate |
| KEGG:04210 | 1.55036637537e-05 | 0.5 | MAP2K1 MAP2K2 RAF1 KRAS | Apoptosis |
| WP:WP3929 | 1.58008323692e-05 | 0.5 | MAP2K1 BRAF RAF1 KRAS | Chemokine signaling pathway |
| HP:0001531 | 1.59796109097e-05 | 0.5 | MAP2K1 KRAS BRAF MAP2K2 | Failure to thrive in infancy |
| KEGG:04072 | 1.60085198137e-05 | 0.5 | MAP2K1 MAP2K2 RAF1 KRAS | Phospholipase D signaling pathway |
| KEGG:04062 | 1.8151604603e-05 | 0.5 | MAP2K1 BRAF RAF1 KRAS | Chemokine signaling pathway |
| KEGG:04140 | 1.98942136633e-05 | 0.5 | MAP2K1 MAP2K2 RAF1 KRAS | Autophagy - animal |
| HP:0000962 | 2.03090839604e-05 | 0.625 | MAP2K1 KRAS BRAF RAF1 MAP2K2 | Hyperkeratosis |
| HP:0001654 | 2.07914168322e-05 | 0.625 | MAP2K1 KRAS BRAF RAF1 MAP2K2 | Abnormal heart valve morphology |
| KEGG:04921 | 2.11233534927e-05 | 0.5 | MAP2K1 MAP2K2 RAF1 KRAS | Oxytocin signaling pathway |
| WP:WP4239 | 2.22351089397e-05 | 0.5 | MAP2K1 MAP2K2 RAF1 KRAS | Epithelial to mesenchymal transition in colorectal cancer |
| HP:0001639 | 2.28128908501e-05 | 0.625 | MAP2K1 KRAS BRAF RAF1 MAP2K2 | Hypertrophic cardiomyopathy |
| WP:WP2380 | 2.29039463186e-05 | 0.5 | MAP2K1 KSR1 MAP2K2 RAF1 | Brain-Derived Neurotrophic Factor (BDNF) signaling pathway |
| HP:0011381 | 2.42910943475e-05 | 0.375 | BRAF RAF1 KRAS | Aplasia of the semicircular canal |
| WP:WP3676 | 2.53462506104e-05 | 0.375 | MAP2K1 BRAF KRAS | BDNF-TrkB Signaling |
| HP:0000973 | 2.54674084093e-05 | 0.5 | MAP2K1 KRAS BRAF MAP2K2 | Cutis laxa |
| HP:0031653 | 2.5556783592e-05 | 0.625 | MAP2K1 KRAS BRAF RAF1 MAP2K2 | Abnormal heart valve physiology |
| HP:0000767 | 2.79359764595e-05 | 0.625 | MAP2K1 KRAS BRAF RAF1 MAP2K2 | Pectus excavatum |
| KEGG:04218 | 2.81393582313e-05 | 0.5 | MAP2K1 MAP2K2 RAF1 KRAS | Cellular senescence |
| HP:0000508 | 2.91765587758e-05 | 0.75 | MAP2K1 RAB3GAP1 BRAF KRAS MAP2K2 RAF1 | Ptosis |
| HP:0003196 | 2.91899745418e-05 | 0.625 | RAB3GAP1 MAP2K1 KRAS BRAF MAP2K2 | Short nose |
| HP:0100538 | 2.99333731359e-05 | 0.5 | MAP2K1 KRAS BRAF MAP2K2 | Abnormality of the supraorbital ridges |
| HP:0000377 | 3.05525702647e-05 | 0.75 | MAP2K1 RAB3GAP1 BRAF KRAS MAP2K2 RAF1 | Abnormality of the pinna |
| WP:WP313 | 3.05636086615e-05 | 0.375 | MAP2K1 MAP2K2 RAF1 | Signaling of Hepatocyte Growth Factor Receptor |
| HP:0000369 | 3.34664991106e-05 | 0.75 | MAP2K1 RAB3GAP1 BRAF KRAS MAP2K2 RAF1 | Low-set ears |
| HP:0002120 | 3.39366930009e-05 | 0.625 | RAB3GAP1 MAP2K1 KRAS BRAF MAP2K2 | Cerebral cortical atrophy |
| CORUM:5873 | 3.50546248845e-05 | 0.25 | MAP2K1 RAF1 | RAF1-MAP2K1-YWHAE complex |
| CORUM:5919 | 3.50546248845e-05 | 0.25 | BRAF RAF1 | BRAF-RAF1-14-3-3 complex |
| HP:0000028 | 3.54020893029e-05 | 0.75 | MAP2K1 RAB3GAP1 BRAF KRAS MAP2K2 RAF1 | Cryptorchidism |
| KEGG:05206 | 3.86997445046e-05 | 0.5 | MAP2K1 MAP2K2 RAF1 KRAS | MicroRNAs in cancer |
| HP:0000470 | 4.52708914805e-05 | 0.625 | MAP2K1 KRAS BRAF RAF1 MAP2K2 | Short neck |
| HP:0002223 | 4.53446775573e-05 | 0.375 | KRAS BRAF MAP2K2 | Absent eyebrow |
| WP:WP2332 | 4.66191279414e-05 | 0.375 | MAP2K1 MAP2K2 RAF1 | Interleukin-11 Signaling Pathway |
| KEGG:05167 | 4.72182145868e-05 | 0.5 | MAP2K1 MAP2K2 RAF1 KRAS | Kaposi sarcoma-associated herpesvirus infection |
| HP:0000357 | 4.75329136024e-05 | 0.75 | MAP2K1 RAB3GAP1 BRAF KRAS MAP2K2 RAF1 | Abnormal location of ears |
| WP:WP49 | 5.0386348363e-05 | 0.375 | MAP2K1 MAP2K2 RAF1 | IL-2 Signaling Pathway |
| GO:0032270 | 5.14024028403e-05 | 1.0 | MAP2K1 RAB3GAP1 BRAF KRAS RAF1 KSR1 ARAF MAP2K2 | positive regulation of cellular protein metabolic process |
| KEGG:04024 | 5.32071762675e-05 | 0.5 | MAP2K1 BRAF RAF1 MAP2K2 | cAMP signaling pathway |
| HP:0011380 | 5.43999030051e-05 | 0.375 | BRAF RAF1 KRAS | Morphological abnormality of the semicircular canal |
| WP:WP2586 | 5.85165564524e-05 | 0.375 | MAP2K1 KRAS RAF1 | Aryl Hydrocarbon Receptor |
| HP:0000293 | 5.89390627221e-05 | 0.5 | MAP2K1 KRAS BRAF MAP2K2 | Full cheeks |
| HP:0000044 | 6.16048143895e-05 | 0.5 | RAB3GAP1 BRAF RAF1 KRAS | Hypogonadotrophic hypogonadism |
| HP:0001631 | 6.52705622186e-05 | 0.625 | MAP2K1 KRAS BRAF RAF1 MAP2K2 | Atrial septal defect |
| HP:0011994 | 6.64907583592e-05 | 0.625 | MAP2K1 KRAS BRAF RAF1 MAP2K2 | Abnormal atrial septum morphology |
| WP:WP4535 | 6.74740784264e-05 | 0.375 | MAP2K1 MAP2K2 KRAS | Envelope proteins and their potential roles in EDMD physiopathology |
| HP:0000325 | 7.0144551869e-05 | 0.5 | MAP2K1 BRAF RAF1 KRAS | Triangular face |
| HP:0002857 | 7.0144551869e-05 | 0.5 | MAP2K1 KRAS BRAF MAP2K2 | Genu valgum |
| HP:0008404 | 7.3178517337e-05 | 0.5 | MAP2K1 KRAS BRAF MAP2K2 | Nail dystrophy |
| HP:0005120 | 7.83109151391e-05 | 0.625 | MAP2K1 KRAS BRAF RAF1 MAP2K2 | Abnormal cardiac atrium morphology |
| HP:0003319 | 7.83109151391e-05 | 0.625 | MAP2K1 KRAS BRAF RAF1 MAP2K2 | Abnormality of the cervical spine |
| HP:0002648 | 8.14518946632e-05 | 0.75 | MAP2K1 RAB3GAP1 BRAF KRAS MAP2K2 RAF1 | Abnormality of calvarial morphology |
| GO:0051247 | 8.57390443879e-05 | 1.0 | MAP2K1 RAB3GAP1 BRAF KRAS RAF1 KSR1 ARAF MAP2K2 | positive regulation of protein metabolic process |
| WP:WP2795 | 8.80288950484e-05 | 0.375 | MAP2K1 MAP2K2 RAF1 | Cardiac Hypertrophic Response |
| HP:0011376 | 8.85994992257e-05 | 0.375 | BRAF RAF1 KRAS | Morphological abnormality of the vestibule of the inner ear |
| GO:0000165 | 8.94176043995e-05 | 0.875 | MAP2K1 BRAF KRAS KSR1 MAP2K2 ARAF RAF1 | MAPK cascade |
| WP:WP3863 | 9.97049025309e-05 | 0.375 | MAP2K1 MAP2K2 RAF1 | T-Cell antigen Receptor (TCR) pathway during Staphylococcus aureus infection |
| KEGG:05170 | 9.97974309941e-05 | 0.5 | MAP2K1 MAP2K2 RAF1 KRAS | Human immunodeficiency virus 1 infection |
| GO:0031399 | 0.000104558665371 | 1.0 | MAP2K1 RAB3GAP1 BRAF KRAS RAF1 KSR1 ARAF MAP2K2 | regulation of protein modification process |
| HP:0000135 | 0.000105173129605 | 0.625 | MAP2K1 KRAS BRAF RAF1 RAB3GAP1 | Hypogonadism |
| KEGG:05163 | 0.000105931876503 | 0.5 | MAP2K1 MAP2K2 RAF1 KRAS | Human cytomegalovirus infection |
| HP:0001028 | 0.000109195817578 | 0.5 | MAP2K1 KRAS BRAF MAP2K2 | Hemangioma |
| GO:0023014 | 0.000116187920519 | 0.875 | MAP2K1 BRAF KRAS KSR1 MAP2K2 ARAF RAF1 | signal transduction by protein phosphorylation |
| HP:0100742 | 0.000117748499778 | 0.5 | MAP2K1 KRAS BRAF MAP2K2 | Vascular neoplasm |
| HP:0001622 | 0.000117748499778 | 0.5 | MAP2K1 KRAS BRAF MAP2K2 | Premature birth |
| WP:WP304 | 0.000140797899147 | 0.375 | MAP2K1 MAP2K2 RAF1 | Kit receptor signaling pathway |
| HP:0004097 | 0.000145659040835 | 0.625 | MAP2K1 KRAS BRAF RAF1 RAB3GAP1 | Deviation of finger |
| HP:0000256 | 0.000150306099682 | 0.625 | MAP2K1 KRAS BRAF RAF1 MAP2K2 | Macrocephaly |
| HP:0040194 | 0.000150306099682 | 0.625 | MAP2K1 KRAS BRAF RAF1 MAP2K2 | Increased head circumference |
| HP:0000035 | 0.000150927686643 | 0.75 | MAP2K1 RAB3GAP1 BRAF KRAS MAP2K2 RAF1 | Abnormal testis morphology |
| GO:0001934 | 0.000151088389273 | 0.875 | MAP2K1 BRAF KRAS KSR1 MAP2K2 ARAF RAF1 | positive regulation of protein phosphorylation |
| HP:0000768 | 0.000151668410454 | 0.5 | MAP2K1 BRAF RAF1 KRAS | Pectus carinatum |
| HP:0011368 | 0.000155070346725 | 0.625 | MAP2K1 KRAS BRAF RAF1 MAP2K2 | Epidermal thickening |
| HP:0011968 | 0.000164599912928 | 0.75 | MAP2K1 RAB3GAP1 BRAF KRAS MAP2K2 RAF1 | Feeding difficulties |
| HP:0100886 | 0.000164599912928 | 0.75 | MAP2K1 RAB3GAP1 BRAF KRAS MAP2K2 RAF1 | Abnormality of globe location |
| HP:0040070 | 0.000172699737966 | 0.625 | MAP2K1 KRAS BRAF RAF1 MAP2K2 | Abnormal upper limb bone morphology |
| HP:0009484 | 0.000172699737966 | 0.625 | MAP2K1 KRAS BRAF RAF1 RAB3GAP1 | Deviation of the hand or of fingers of the hand |
| HP:0011354 | 0.000174768390603 | 0.75 | MAP2K1 RAB3GAP1 BRAF KRAS MAP2K2 RAF1 | Generalized abnormality of skin |
| HP:0001597 | 0.00017801865249 | 0.625 | RAB3GAP1 MAP2K1 KRAS BRAF MAP2K2 | Abnormality of the nail |
| HP:0001000 | 0.000191887531525 | 0.625 | MAP2K1 KRAS BRAF RAF1 MAP2K2 | Abnormality of skin pigmentation |
| HP:0002683 | 0.000198318517523 | 0.75 | MAP2K1 RAB3GAP1 BRAF KRAS MAP2K2 RAF1 | Abnormality of the calvaria |
| HP:0000969 | 0.000203589936423 | 0.625 | MAP2K1 KRAS BRAF RAF1 MAP2K2 | Edema |
| HP:0100542 | 0.000205410820799 | 0.5 | RAB3GAP1 BRAF RAF1 KRAS | Abnormal localization of kidney |
| HP:0008064 | 0.000205410820799 | 0.5 | MAP2K1 KRAS BRAF MAP2K2 | Ichthyosis |
| HP:0000766 | 0.000206602373834 | 0.625 | MAP2K1 KRAS BRAF RAF1 MAP2K2 | Abnormality of the sternum |
| HP:0000422 | 0.000211915994044 | 0.75 | MAP2K1 RAB3GAP1 BRAF KRAS MAP2K2 RAF1 | Abnormality of the nasal bridge |
| HP:0012210 | 0.000217210067382 | 0.75 | MAP2K1 RAB3GAP1 BRAF KRAS MAP2K2 RAF1 | Abnormal renal morphology |
| HP:0000159 | 0.00021899891227 | 0.75 | MAP2K1 RAB3GAP1 BRAF KRAS MAP2K2 RAF1 | Abnormal lip morphology |
| WP:WP2032 | 0.000221359959089 | 0.375 | MAP2K1 BRAF RAF1 | Human Thyroid Stimulating Hormone (TSH) signaling pathway |
| GO:0042327 | 0.000232184457928 | 0.875 | MAP2K1 BRAF KRAS KSR1 MAP2K2 ARAF RAF1 | positive regulation of phosphorylation |
| HP:0100840 | 0.000240799653472 | 0.5 | MAP2K1 KRAS BRAF MAP2K2 | Aplasia/Hypoplasia of the eyebrow |
| HP:0000494 | 0.000242139928212 | 0.625 | MAP2K1 KRAS BRAF RAF1 MAP2K2 | Downslanted palpebral fissures |
| HP:0001072 | 0.000256204511836 | 0.625 | MAP2K1 KRAS BRAF RAF1 MAP2K2 | Thickened skin |
| HP:0001892 | 0.000263476187464 | 0.625 | MAP2K1 KRAS BRAF RAF1 MAP2K2 | Abnormal bleeding |
| HP:0000174 | 0.000280831935377 | 0.75 | MAP2K1 RAB3GAP1 BRAF KRAS MAP2K2 RAF1 | Abnormal palate morphology |
| WP:WP3932 | 0.000286096620219 | 0.5 | MAP2K1 MAP2K2 RAF1 KRAS | Focal Adhesion-PI3K-Akt-mTOR-signaling pathway |
| HP:0002751 | 0.000289056416216 | 0.5 | MAP2K1 KRAS BRAF RAB3GAP1 | Kyphoscoliosis |
| HP:0002650 | 0.000318005921728 | 0.75 | MAP2K1 RAB3GAP1 BRAF KRAS MAP2K2 RAF1 | Scoliosis |
| HP:0000286 | 0.000327752359813 | 0.625 | MAP2K1 KRAS BRAF RAF1 MAP2K2 | Epicanthus |
| WP:WP2037 | 0.000327767147782 | 0.375 | MAP2K1 MAP2K2 RAF1 | Prolactin Signaling Pathway |
| WP:WP2034 | 0.000327767147782 | 0.375 | MAP2K1 MAP2K2 RAF1 | Leptin signaling pathway |
| HP:0009810 | 0.000332148636562 | 0.625 | MAP2K1 KRAS BRAF RAF1 MAP2K2 | Abnormality of upper limb joint |
| GO:0045937 | 0.000332354906503 | 0.875 | MAP2K1 BRAF KRAS KSR1 MAP2K2 ARAF RAF1 | positive regulation of phosphate metabolic process |
| GO:0010562 | 0.000332354906503 | 0.875 | MAP2K1 BRAF KRAS KSR1 MAP2K2 ARAF RAF1 | positive regulation of phosphorus metabolic process |
| HP:0010490 | 0.000354088011888 | 0.5 | MAP2K1 KRAS BRAF MAP2K2 | Abnormality of the palmar creases |
| WP:WP1544 | 0.000355275761306 | 0.375 | MAP2K1 MAP2K2 RAF1 | MicroRNAs in cardiomyocyte hypertrophy |
| HP:0010318 | 0.000362360009835 | 0.375 | BRAF RAF1 KRAS | Aplasia/Hypoplasia of the abdominal wall musculature |
| HP:0001231 | 0.00036419879787 | 0.5 | MAP2K1 KRAS BRAF MAP2K2 | Abnormal fingernail morphology |
| WP:WP69 | 0.000369585485393 | 0.375 | MAP2K1 MAP2K2 RAF1 | T-Cell antigen Receptor (TCR) Signaling Pathway |
| GO:0043406 | 0.000378328505435 | 0.625 | MAP2K1 KSR1 BRAF RAF1 MAP2K2 | positive regulation of MAP kinase activity |
| HP:0000032 | 0.000389943214311 | 0.75 | MAP2K1 RAB3GAP1 BRAF KRAS MAP2K2 RAF1 | Abnormality of male external genitalia |
| HP:0001018 | 0.000395826148734 | 0.5 | MAP2K1 KRAS BRAF MAP2K2 | Abnormal palmar dermatoglyphics |
| HP:0002298 | 0.0003973269126 | 0.375 | KRAS BRAF MAP2K2 | Absent hair |
| REAC:R-HSA-168256 | 0.000398753808164 | 0.875 | MAP2K1 BRAF KRAS KSR1 MAP2K2 ARAF RAF1 | Immune System |
| HP:0002979 | 0.000406810175843 | 0.5 | MAP2K1 KRAS BRAF MAP2K2 | Bowing of the legs |
| HP:0011032 | 0.000430387965995 | 0.625 | MAP2K1 KRAS BRAF RAF1 MAP2K2 | Abnormality of fluid regulation |
| WP:WP4172 | 0.000450048304229 | 0.5 | MAP2K1 MAP2K2 RAF1 KRAS | PI3K-Akt Signaling Pathway |
| HP:0003006 | 0.000473844223558 | 0.375 | BRAF RAF1 KRAS | Neuroblastoma |
| HP:0004376 | 0.000473844223558 | 0.375 | BRAF RAF1 KRAS | Neuroblastic tumor |
| HP:0030067 | 0.000473844223558 | 0.375 | BRAF RAF1 KRAS | Peripheral primitive neuroectodermal neoplasm |
| HP:0011869 | 0.000473844223558 | 0.375 | BRAF RAF1 KRAS | Abnormal platelet function |
| HP:0010461 | 0.000474855750717 | 0.75 | MAP2K1 RAB3GAP1 BRAF KRAS MAP2K2 RAF1 | Abnormality of the male genitalia |
| HP:0001638 | 0.000475604177784 | 0.625 | MAP2K1 KRAS BRAF RAF1 MAP2K2 | Cardiomyopathy |
| HP:0000811 | 0.000478272564455 | 0.75 | MAP2K1 RAB3GAP1 BRAF KRAS MAP2K2 RAF1 | Abnormal external genitalia |
| WP:WP2355 | 0.000480565625947 | 0.375 | MAP2K1 BRAF RAF1 | Corticotropin-releasing hormone signaling pathway |
| HP:0010674 | 0.000488645308224 | 0.75 | MAP2K1 RAB3GAP1 BRAF KRAS MAP2K2 RAF1 | Abnormality of the curvature of the vertebral column |
| HP:0000356 | 0.000502764586936 | 0.75 | MAP2K1 RAB3GAP1 BRAF KRAS MAP2K2 RAF1 | Abnormality of the outer ear |
| KEGG:04151 | 0.000509455935862 | 0.5 | MAP2K1 MAP2K2 RAF1 KRAS | PI3K-Akt signaling pathway |
| HP:0001928 | 0.000516194815118 | 0.5 | MAP2K1 BRAF RAF1 KRAS | Abnormality of coagulation |
| CORUM:7557 | 0.000524831455609 | 0.25 | MAP2K1 MAP2K2 | LGR4-RSPO supercomplex |
| KEGG:04625 | 0.000525250641096 | 0.375 | KSR1 KRAS RAF1 | C-type lectin receptor signaling pathway |
| HP:0001260 | 0.000543853168563 | 0.625 | MAP2K1 KRAS BRAF RAF1 MAP2K2 | Dysarthria |
| WP:WP231 | 0.00055289541168 | 0.375 | KSR1 KRAS RAF1 | TNF alpha Signaling Pathway |
| HP:0004426 | 0.000557110821358 | 0.5 | MAP2K1 KRAS BRAF MAP2K2 | Abnormality of the cheek |
| HP:0030065 | 0.000559570634138 | 0.375 | BRAF RAF1 KRAS | Primitive neuroectodermal tumor |
| HP:0011821 | 0.0005626641231 | 0.75 | MAP2K1 RAB3GAP1 BRAF KRAS MAP2K2 RAF1 | Abnormality of facial skeleton |
| HP:0000606 | 0.000571272016088 | 0.5 | MAP2K1 KRAS BRAF MAP2K2 | Abnormality of the periorbital region |
| WP:WP615 | 0.000572037915643 | 0.375 | MAP2K1 BRAF RAF1 | Senescence and Autophagy in Cancer |
| WP:WP4269 | 0.000573702400868 | 0.25 | MAP2K1 MAP2K2 | Ethanol metabolism resulting in production of ROS by CYP2E1 |
| HP:0001595 | 0.000594757387888 | 0.75 | MAP2K1 RAB3GAP1 BRAF KRAS MAP2K2 RAF1 | Abnormal hair morphology |
| KEGG:05165 | 0.000594895172942 | 0.5 | MAP2K1 MAP2K2 RAF1 KRAS | Human papillomavirus infection |
| HP:0001637 | 0.000605288137177 | 0.625 | MAP2K1 KRAS BRAF RAF1 MAP2K2 | Abnormal myocardium morphology |
| HP:0000276 | 0.000630616443076 | 0.5 | MAP2K1 KRAS BRAF MAP2K2 | Long face |
| HP:0000288 | 0.000634301653838 | 0.625 | RAB3GAP1 MAP2K1 KRAS BRAF MAP2K2 | Abnormality of the philtrum |
| REAC:R-HSA-5210891 | 0.000670718000013 | 0.25 | MAP2K1 MAP2K2 | Uptake and function of anthrax toxins |
| HP:0000280 | 0.000678052208658 | 0.5 | MAP2K1 KRAS BRAF MAP2K2 | Coarse facial features |
| HP:0000080 | 0.000711685435365 | 0.625 | MAP2K1 KRAS BRAF RAF1 RAB3GAP1 | Abnormality of reproductive system physiology |
| HP:0000463 | 0.000744659087775 | 0.625 | RAB3GAP1 MAP2K1 KRAS BRAF MAP2K2 | Anteverted nares |
| HP:0001671 | 0.000841627134726 | 0.625 | MAP2K1 KRAS BRAF RAF1 MAP2K2 | Abnormal cardiac septum morphology |
| HP:0005288 | 0.000850916085232 | 0.625 | RAB3GAP1 MAP2K1 KRAS BRAF MAP2K2 | Abnormality of the nares |
| HP:0000499 | 0.000855545633287 | 0.5 | MAP2K1 KRAS BRAF MAP2K2 | Abnormal eyelash morphology |
| REAC:R-HSA-162582 | 0.000865241887421 | 0.875 | MAP2K1 BRAF KRAS KSR1 MAP2K2 ARAF RAF1 | Signal Transduction |
| HP:0010991 | 0.000939580488264 | 0.375 | BRAF RAF1 KRAS | Abnormal morphology of the abdominal musculature |
| HP:0008357 | 0.00099602173043 | 0.25 | MAP2K1 BRAF | Reduced factor XIII activity |
| HP:0100697 | 0.00099602173043 | 0.25 | MAP2K1 BRAF | Neurofibrosarcoma |
| HP:0000917 | 0.00099602173043 | 0.25 | MAP2K1 BRAF | Superior pectus carinatum |
| HP:0100729 | 0.00099891831074 | 0.5 | MAP2K1 KRAS BRAF MAP2K2 | Large face |
| HP:0002208 | 0.00100487910011 | 0.375 | BRAF RAF1 KRAS | Coarse hair |
| HP:0011362 | 0.00102168079078 | 0.625 | RAB3GAP1 KRAS BRAF RAF1 MAP2K2 | Abnormal hair quantity |
| HP:0000648 | 0.00103251254955 | 0.625 | RAB3GAP1 MAP2K1 KRAS BRAF MAP2K2 | Optic atrophy |
| HP:0002981 | 0.00104298101006 | 0.5 | MAP2K1 KRAS BRAF MAP2K2 | Abnormality of the calf |
| HP:0001641 | 0.00107312284216 | 0.375 | BRAF RAF1 KRAS | Abnormal pulmonary valve morphology |
| HP:0004415 | 0.00107312284216 | 0.375 | BRAF RAF1 KRAS | Pulmonary artery stenosis |
| HP:0000995 | 0.00107312284216 | 0.375 | BRAF RAF1 KRAS | Melanocytic nevus |
| HP:0000077 | 0.00107955525204 | 0.75 | MAP2K1 RAB3GAP1 BRAF KRAS MAP2K2 RAF1 | Abnormality of the kidney |
| HP:0006487 | 0.00115946769498 | 0.5 | MAP2K1 KRAS BRAF MAP2K2 | Bowing of the long bones |
| HP:0002059 | 0.00120621572236 | 0.625 | RAB3GAP1 MAP2K1 KRAS BRAF MAP2K2 | Cerebral atrophy |
| GO:0071902 | 0.00121284168955 | 0.625 | MAP2K1 KSR1 BRAF RAF1 MAP2K2 | positive regulation of protein serine/threonine kinase activity |
| HP:0200007 | 0.00123385220625 | 0.5 | MAP2K1 KRAS BRAF MAP2K2 | Abnormal size of the palpebral fissures |
| HP:0011138 | 0.00123600190895 | 0.75 | MAP2K1 RAB3GAP1 BRAF KRAS MAP2K2 RAF1 | Abnormality of skin adnexa morphology |
| HP:0006504 | 0.00125941888856 | 0.5 | MAP2K1 KRAS BRAF MAP2K2 | Anomaly of the limb diaphyses |
| HP:0007369 | 0.00126899722283 | 0.625 | RAB3GAP1 MAP2K1 KRAS BRAF MAP2K2 | Atrophy/Degeneration affecting the cerebrum |
| HP:0010935 | 0.00127405028424 | 0.75 | MAP2K1 RAB3GAP1 BRAF KRAS MAP2K2 RAF1 | Abnormality of the upper urinary tract |
| HP:0200006 | 0.00130789192246 | 0.625 | MAP2K1 KRAS BRAF RAF1 MAP2K2 | Slanting of the palpebral fissure |
| HP:0040211 | 0.00133848911928 | 0.5 | MAP2K1 KRAS BRAF MAP2K2 | Abnormality of the skin of the palm |
| HP:0004322 | 0.00134497629625 | 0.75 | MAP2K1 RAB3GAP1 BRAF KRAS MAP2K2 RAF1 | Short stature |
| HP:0000474 | 0.00137682655036 | 0.375 | BRAF RAF1 KRAS | Thickened nuchal skin fold |
| HP:0000429 | 0.00148750524076 | 0.625 | RAB3GAP1 MAP2K1 KRAS BRAF MAP2K2 | Abnormality of the nasal alae |
| WP:WP22 | 0.00152740874202 | 0.25 | MAP2K1 MAP2K2 | IL-9 Signaling Pathway |
| WP:WP3915 | 0.00154837646491 | 0.375 | MAP2K1 MAP2K2 RAF1 | Angiopoietin Like Protein 8 Regulatory Pathway |
| WP:WP366 | 0.00154837646491 | 0.375 | MAP2K1 MAP2K2 RAF1 | TGF-beta Signaling Pathway |
| HP:0012243 | 0.00162412867354 | 0.75 | MAP2K1 RAB3GAP1 BRAF KRAS MAP2K2 RAF1 | Abnormal reproductive system morphology |
| HP:0011390 | 0.00163865378067 | 0.375 | BRAF RAF1 KRAS | Morphological abnormality of the inner ear |
| HP:0000915 | 0.00165959031572 | 0.25 | MAP2K1 BRAF | Pectus excavatum of inferior sternum |
| HP:0004859 | 0.00165959031572 | 0.25 | MAP2K1 BRAF | Amegakaryocytic thrombocytopenia |
| HP:0004841 | 0.00165959031572 | 0.25 | MAP2K1 BRAF | Reduced factor XII activity |
| HP:0011800 | 0.00166036462722 | 0.5 | RAB3GAP1 BRAF RAF1 KRAS | Midface retrusion |
| GO:0001932 | 0.00174730853446 | 0.875 | MAP2K1 BRAF KRAS KSR1 MAP2K2 ARAF RAF1 | regulation of protein phosphorylation |
| HP:0000316 | 0.00175130581442 | 0.625 | MAP2K1 KRAS BRAF RAF1 MAP2K2 | Hypertelorism |
| HP:0008373 | 0.00175130581442 | 0.625 | MAP2K1 KRAS BRAF RAF1 RAB3GAP1 | Puberty and gonadal disorders |
| HP:0012795 | 0.00176790510269 | 0.625 | RAB3GAP1 MAP2K1 KRAS BRAF MAP2K2 | Abnormality of the optic disc |
| GO:0043405 | 0.00177398727307 | 0.625 | MAP2K1 KSR1 BRAF RAF1 MAP2K2 | regulation of MAP kinase activity |
| HP:0000178 | 0.00179059130684 | 0.5 | RAB3GAP1 BRAF RAF1 KRAS | Abnormality of lower lip |
| GO:0032268 | 0.00179077708229 | 1.0 | MAP2K1 RAB3GAP1 BRAF KRAS RAF1 KSR1 ARAF MAP2K2 | regulation of cellular protein metabolic process |
| HP:0000940 | 0.00185848223486 | 0.5 | MAP2K1 KRAS BRAF MAP2K2 | Abnormal diaphysis morphology |
| HP:0000925 | 0.00194950336279 | 0.75 | MAP2K1 RAB3GAP1 BRAF KRAS MAP2K2 RAF1 | Abnormality of the vertebral column |
| HP:0001155 | 0.00194950336279 | 0.75 | MAP2K1 RAB3GAP1 BRAF KRAS MAP2K2 RAF1 | Abnormality of the hand |
| HP:0012444 | 0.00199527165215 | 0.625 | RAB3GAP1 MAP2K1 KRAS BRAF MAP2K2 | Brain atrophy |
| HP:0000002 | 0.00200488965669 | 0.75 | MAP2K1 RAB3GAP1 BRAF KRAS MAP2K2 RAF1 | Abnormality of body height |
| GO:0032147 | 0.00203112182221 | 0.625 | MAP2K1 KSR1 BRAF RAF1 MAP2K2 | activation of protein kinase activity |
| HP:0002861 | 0.0020364170767 | 0.375 | BRAF RAF1 KRAS | Melanoma |
| HP:0030063 | 0.0020364170767 | 0.375 | BRAF RAF1 KRAS | Neuroepithelial neoplasm |
| HP:0000347 | 0.0020696986178 | 0.625 | MAP2K1 KRAS BRAF RAF1 RAB3GAP1 | Micrognathia |
| HP:0009118 | 0.00212694862857 | 0.625 | MAP2K1 KRAS BRAF RAF1 RAB3GAP1 | Aplasia/Hypoplasia of the mandible |
| HP:0001680 | 0.00214496944687 | 0.375 | MAP2K1 BRAF KRAS | Coarctation of aorta |
| HP:0002974 | 0.00214496944687 | 0.375 | BRAF RAF1 KRAS | Radioulnar synostosis |
| HP:0030060 | 0.00214496944687 | 0.375 | BRAF RAF1 KRAS | Nervous tissue neoplasm |
| HP:0030061 | 0.00214496944687 | 0.375 | BRAF RAF1 KRAS | Neuroectodermal neoplasm |
| KEGG:04022 | 0.00215976810771 | 0.375 | MAP2K1 MAP2K2 RAF1 | cGMP-PKG signaling pathway |
| KEGG:04934 | 0.00215976810771 | 0.375 | MAP2K1 BRAF MAP2K2 | Cushing syndrome |
| HP:0009116 | 0.00230626244393 | 0.625 | MAP2K1 KRAS BRAF RAF1 RAB3GAP1 | Aplasia/Hypoplasia involving bones of the skull |
| WP:WP1984 | 0.00242090981495 | 0.375 | ARAF BRAF KRAS | Integrated Breast Cancer Pathway |
| HP:0008070 | 0.00247281651547 | 0.5 | MAP2K1 KRAS BRAF MAP2K2 | Sparse hair |
| HP:0100769 | 0.00248871678952 | 0.25 | MAP2K1 BRAF | Synovitis |
| HP:0100836 | 0.00249350467565 | 0.375 | BRAF RAF1 KRAS | Malignant neoplasm of the central nervous system |
| KEGG:05164 | 0.00249578640531 | 0.375 | MAP2K1 MAP2K2 RAF1 | Influenza A |
| HP:0008050 | 0.00254146211123 | 0.625 | MAP2K1 KRAS BRAF RAF1 MAP2K2 | Abnormality of the palpebral fissures |
| HP:0001382 | 0.00260297760598 | 0.5 | RAB3GAP1 BRAF RAF1 KRAS | Joint hypermobility |
| WP:WP712 | 0.00266937646566 | 0.25 | MAP2K1 BRAF | Estrogen signaling pathway |
| HP:0011792 | 0.00269253652949 | 0.5 | MAP2K1 BRAF RAF1 KRAS | Neoplasm by histology |
| WP:WP205 | 0.00293552516575 | 0.25 | MAP2K1 MAP2K2 | IL-7 Signaling Pathway |
| HP:0000177 | 0.00294192139247 | 0.625 | RAB3GAP1 MAP2K1 KRAS BRAF MAP2K2 | Abnormality of upper lip |
| WP:WP481 | 0.00295765675347 | 0.375 | MAP2K1 MAP2K2 RAF1 | Insulin Signaling |
| HP:0000240 | 0.00295800074077 | 0.75 | MAP2K1 RAB3GAP1 BRAF KRAS MAP2K2 RAF1 | Abnormality of skull size |
| GO:0051246 | 0.00296982294334 | 1.0 | MAP2K1 RAB3GAP1 BRAF KRAS RAF1 KSR1 ARAF MAP2K2 | regulation of protein metabolic process |
| HP:0011425 | 0.00301395088993 | 0.375 | BRAF RAF1 KRAS | Fetal ultrasound soft marker |
| HP:0011357 | 0.00302412121558 | 0.5 | MAP2K1 KRAS BRAF MAP2K2 | Abnormality of hair density |
| HP:0002815 | 0.00307385500324 | 0.5 | MAP2K1 KRAS BRAF MAP2K2 | Abnormality of the knee |
| HP:0002817 | 0.00314823086166 | 0.75 | MAP2K1 RAB3GAP1 BRAF KRAS MAP2K2 RAF1 | Abnormality of the upper limb |
| HP:0000078 | 0.00319733231997 | 0.75 | MAP2K1 RAB3GAP1 BRAF KRAS MAP2K2 RAF1 | Abnormality of the genital system |
| HP:0001634 | 0.00329918963144 | 0.375 | BRAF RAF1 KRAS | Mitral valve prolapse |
| HP:0040068 | 0.00334844254703 | 0.75 | MAP2K1 RAB3GAP1 BRAF KRAS MAP2K2 RAF1 | Abnormality of limb bone |
| HP:0002813 | 0.00334844254703 | 0.75 | MAP2K1 RAB3GAP1 BRAF KRAS MAP2K2 RAF1 | Abnormality of limb bone morphology |
| HP:0008625 | 0.00348326758344 | 0.25 | BRAF RAF1 | Severe sensorineural hearing impairment |
| HP:0012714 | 0.00348326758344 | 0.25 | BRAF RAF1 | Severe hearing impairment |
| HP:0030966 | 0.00375972569537 | 0.375 | BRAF RAF1 KRAS | Abnormal pulmonary artery morphology |
| HP:0001482 | 0.00375972569537 | 0.375 | BRAF RAF1 KRAS | Subcutaneous nodule |
| HP:0000343 | 0.0037772368825 | 0.5 | MAP2K1 KRAS BRAF MAP2K2 | Long philtrum |
| WP:WP2197 | 0.00380929807672 | 0.25 | MAP2K1 RAF1 | Endothelin Pathways |
| WP:WP2870 | 0.00380929807672 | 0.25 | KRAS RAF1 | Extracellular vesicle-mediated signaling in recipient cells |
| HP:0007367 | 0.00389215771254 | 0.625 | RAB3GAP1 MAP2K1 KRAS BRAF MAP2K2 | Atrophy/Degeneration affecting the central nervous system |
| HP:0000587 | 0.0039233799373 | 0.625 | RAB3GAP1 MAP2K1 KRAS BRAF MAP2K2 | Abnormality of the optic nerve |
| GO:0042325 | 0.00392999514621 | 0.875 | MAP2K1 BRAF KRAS KSR1 MAP2K2 ARAF RAF1 | regulation of phosphorylation |
| HP:0001156 | 0.00395521203096 | 0.5 | MAP2K1 BRAF RAF1 KRAS | Brachydactyly |
| HP:0009122 | 0.00401823706933 | 0.625 | MAP2K1 KRAS BRAF RAF1 RAB3GAP1 | Aplasia/hypoplasia affecting bones of the axial skeleton |
| HP:0000545 | 0.00413934167929 | 0.5 | MAP2K1 KRAS BRAF MAP2K2 | Myopia |
| HP:0011458 | 0.00425741985542 | 0.75 | MAP2K1 RAB3GAP1 BRAF KRAS MAP2K2 RAF1 | Abdominal symptom |
| HP:0000366 | 0.00438410454079 | 0.75 | MAP2K1 RAB3GAP1 BRAF KRAS MAP2K2 RAF1 | Abnormality of the nose |
| HP:0001547 | 0.00439465804469 | 0.5 | MAP2K1 BRAF RAF1 KRAS | Abnormality of the rib cage |
| HP:0001197 | 0.00441596721313 | 0.625 | MAP2K1 KRAS BRAF RAF1 MAP2K2 | Abnormality of prenatal development or birth |
| HP:0040157 | 0.00443739277658 | 0.375 | BRAF RAF1 KRAS | Abnormal intermamillary distance |
| HP:0006610 | 0.00443739277658 | 0.375 | BRAF RAF1 KRAS | Wide intermamillary distance |
| HP:0100871 | 0.00459368220434 | 0.5 | MAP2K1 KRAS BRAF MAP2K2 | Abnormality of the palm |
| HP:0011355 | 0.00480731272754 | 0.625 | MAP2K1 KRAS BRAF RAF1 MAP2K2 | Localized skin lesion |
| KEGG:05020 | 0.00489222565408 | 0.25 | MAP2K1 MAP2K2 | Prion diseases |
| HP:0011793 | 0.00514747238339 | 0.625 | MAP2K1 KRAS BRAF RAF1 MAP2K2 | Neoplasm by anatomical site |
| WP:WP3972 | 0.00514971121482 | 0.25 | MAP2K1 RAF1 | PDGFR-beta pathway |
| HP:0011844 | 0.00516213833898 | 0.75 | MAP2K1 RAB3GAP1 BRAF KRAS MAP2K2 RAF1 | Abnormal appendicular skeleton morphology |
| KEGG:04510 | 0.00516683673469 | 0.375 | MAP2K1 BRAF RAF1 | Focal adhesion |
| HP:0001633 | 0.00519141480173 | 0.375 | BRAF RAF1 KRAS | Abnormal mitral valve morphology |
| WP:WP306 | 0.00535380321151 | 0.375 | MAP2K1 BRAF RAF1 | Focal Adhesion |
| HP:0000765 | 0.00538461707606 | 0.625 | MAP2K1 KRAS BRAF RAF1 MAP2K2 | Abnormality of the thorax |
| HP:0004414 | 0.00539231561202 | 0.375 | BRAF RAF1 KRAS | Abnormality of the pulmonary artery |
| HP:0011218 | 0.00545735168842 | 0.5 | MAP2K1 KRAS BRAF MAP2K2 | Abnormal shape of the frontal region |
| HP:0002007 | 0.00545735168842 | 0.5 | MAP2K1 KRAS BRAF MAP2K2 | Frontal bossing |
| HP:0000238 | 0.00577034281269 | 0.5 | MAP2K1 KRAS BRAF MAP2K2 | Hydrocephalus |
| KEGG:05166 | 0.00584304455133 | 0.375 | MAP2K1 MAP2K2 KRAS | Human T-cell leukemia virus 1 infection |
| HP:0001252 | 0.00602276773411 | 0.75 | MAP2K1 RAB3GAP1 BRAF KRAS MAP2K2 RAF1 | Muscular hypotonia |
| HP:0030448 | 0.00602575533395 | 0.375 | MAP2K1 BRAF KRAS | Soft tissue sarcoma |
| HP:0200036 | 0.0062473531373 | 0.375 | BRAF RAF1 KRAS | Skin nodule |
| HP:0001510 | 0.00636361355162 | 0.75 | MAP2K1 RAB3GAP1 BRAF KRAS MAP2K2 RAF1 | Growth delay |
| HP:0000277 | 0.0063748778182 | 0.625 | MAP2K1 KRAS BRAF RAF1 RAB3GAP1 | Abnormality of the mandible |
| HP:0002664 | 0.0063748778182 | 0.625 | MAP2K1 KRAS BRAF RAF1 MAP2K2 | Neoplasm |
| HP:0010438 | 0.00652310326714 | 0.5 | MAP2K1 KRAS BRAF MAP2K2 | Abnormal ventricular septum morphology |
| HP:0010938 | 0.0066554649482 | 0.625 | RAB3GAP1 MAP2K1 KRAS BRAF MAP2K2 | Abnormality of the external nose |
| HP:0001263 | 0.00728580236648 | 0.75 | MAP2K1 RAB3GAP1 BRAF KRAS MAP2K2 RAF1 | Global developmental delay |
| HP:0001872 | 0.00734636010016 | 0.5 | MAP2K1 BRAF RAF1 KRAS | Abnormal thrombocyte morphology |
| HP:0000486 | 0.00734817845465 | 0.625 | MAP2K1 KRAS BRAF RAF1 MAP2K2 | Strabismus |
| HP:0000914 | 0.00745813121128 | 0.25 | MAP2K1 BRAF | Shield chest |
| HP:0002046 | 0.00745813121128 | 0.25 | MAP2K1 MAP2K2 | Heat intolerance |
| REAC:R-HSA-112409 | 0.00761952471968 | 0.25 | MAP2K1 MAP2K2 | RAF-independent MAPK1/3 activation |
| HP:0000290 | 0.007876910085 | 0.625 | MAP2K1 KRAS BRAF RAF1 MAP2K2 | Abnormality of the forehead |
| HP:0100238 | 0.00795116344928 | 0.375 | BRAF RAF1 KRAS | Synostosis involving bones of the upper limbs |
| GO:0019220 | 0.00801976019969 | 0.875 | MAP2K1 BRAF KRAS KSR1 MAP2K2 ARAF RAF1 | regulation of phosphate metabolic process |
| GO:0051174 | 0.00806630677272 | 0.875 | MAP2K1 BRAF KRAS KSR1 MAP2K2 ARAF RAF1 | regulation of phosphorus metabolic process |
| HP:0030791 | 0.00815229971493 | 0.625 | MAP2K1 KRAS BRAF RAF1 RAB3GAP1 | Abnormal jaw morphology |
| HP:0001508 | 0.00832114594098 | 0.625 | RAB3GAP1 MAP2K1 KRAS BRAF MAP2K2 | Failure to thrive |
| WP:WP3888 | 0.00841578083452 | 0.375 | MAP2K1 MAP2K2 RAF1 | VEGFA-VEGFR2 Signaling Pathway |
| REAC:R-HSA-445144 | 0.0084638639205 | 0.25 | MAP2K1 MAP2K2 | Signal transduction by L1 |
| HP:0000549 | 0.00866711703966 | 0.625 | MAP2K1 KRAS BRAF RAF1 MAP2K2 | Abnormal conjugate eye movement |
| HP:0005105 | 0.0087258661226 | 0.625 | RAB3GAP1 MAP2K1 KRAS BRAF MAP2K2 | Abnormal nasal morphology |
| REAC:R-HSA-5339562 | 0.00935228350379 | 0.25 | MAP2K1 MAP2K2 | Uptake and actions of bacterial toxins |
| REAC:R-HSA-5621575 | 0.00935228350379 | 0.25 | KRAS RAF1 | CD209 (DC-SIGN) signaling |
| WP:WP2526 | 0.00986432600459 | 0.25 | MAP2K1 RAF1 | PDGF Pathway |
| HP:0002808 | 0.00991817299115 | 0.5 | MAP2K1 KRAS BRAF RAB3GAP1 | Kyphosis |
| HP:0006705 | 0.00993705207292 | 0.375 | BRAF RAF1 KRAS | Abnormal atrioventricular valve morphology |
| CORUM:0000000 | 0.00993810898821 | 0.875 | MAP2K1 BRAF KRAS KSR1 MAP2K2 ARAF RAF1 | CORUM root |
| HP:0011121 | 0.0103392206135 | 0.75 | MAP2K1 RAB3GAP1 BRAF KRAS MAP2K2 RAF1 | Abnormality of skin morphology |
| WP:WP2203 | 0.010367401671 | 0.25 | MAP2K1 MAP2K2 | Thymic Stromal LymphoPoietin (TSLP) Signaling Pathway |
| HP:0003764 | 0.0105591815374 | 0.375 | BRAF RAF1 KRAS | Nevus |
| HP:0000079 | 0.0107352206567 | 0.75 | MAP2K1 RAB3GAP1 BRAF KRAS MAP2K2 RAF1 | Abnormality of the urinary system |
| HP:0004930 | 0.0108796714446 | 0.375 | BRAF RAF1 KRAS | Abnormality of the pulmonary vasculature |
| WP:WP286 | 0.0108828459268 | 0.25 | MAP2K1 RAF1 | IL-3 Signaling Pathway |
| WP:WP364 | 0.0108828459268 | 0.25 | MAP2K1 MAP2K2 | IL-6 signaling pathway |
| HP:0000639 | 0.0109182372354 | 0.625 | MAP2K1 KRAS BRAF RAF1 MAP2K2 | Nystagmus |
| GO:0051173 | 0.0112903049081 | 1.0 | MAP2K1 RAB3GAP1 BRAF KRAS RAF1 KSR1 ARAF MAP2K2 | positive regulation of nitrogen compound metabolic process |
| HP:0012547 | 0.0116393290133 | 0.625 | MAP2K1 KRAS BRAF RAF1 MAP2K2 | Abnormal involuntary eye movements |
| HP:0001999 | 0.0117134532357 | 0.625 | MAP2K1 KRAS BRAF RAF1 MAP2K2 | Abnormal facial shape |
| HP:0001249 | 0.0123456138509 | 0.75 | MAP2K1 RAB3GAP1 BRAF KRAS MAP2K2 RAF1 | Intellectual disability |
| HP:0031703 | 0.0123456138509 | 0.75 | MAP2K1 RAB3GAP1 BRAF KRAS MAP2K2 RAF1 | Abnormal ear morphology |
| HP:0100242 | 0.0125787875864 | 0.375 | MAP2K1 BRAF KRAS | Sarcoma |
| WP:WP4566 | 0.013068107134 | 0.25 | MAP2K1 MAP2K2 | Translation inhibitors in chronically activated PDGFRA cells |
| HP:0030084 | 0.0131031690513 | 0.5 | MAP2K1 BRAF RAF1 KRAS | Clinodactyly |
| HP:0000975 | 0.0133046690796 | 0.375 | MAP2K1 BRAF MAP2K2 | Hyperhidrosis |
| GO:0071900 | 0.0133260796604 | 0.625 | MAP2K1 KSR1 BRAF RAF1 MAP2K2 | regulation of protein serine/threonine kinase activity |
| HP:0004349 | 0.0135486926517 | 0.5 | MAP2K1 KRAS BRAF RAB3GAP1 | Reduced bone mineral density |
| HP:0002353 | 0.0135486926517 | 0.5 | MAP2K1 KRAS BRAF MAP2K2 | EEG abnormality |
| HP:0031816 | 0.0136522592358 | 0.75 | MAP2K1 RAB3GAP1 BRAF KRAS MAP2K2 RAF1 | Abnormal oral morphology |
| HP:0000163 | 0.0136522592358 | 0.75 | MAP2K1 RAB3GAP1 BRAF KRAS MAP2K2 RAF1 | Abnormal oral cavity morphology |
| HP:0025032 | 0.0142057711958 | 0.75 | MAP2K1 RAB3GAP1 BRAF KRAS MAP2K2 RAF1 | Abnormality of digestive system physiology |
| HP:0001367 | 0.0145518577136 | 0.625 | MAP2K1 KRAS BRAF RAF1 MAP2K2 | Abnormal joint morphology |
| GO:0043410 | 0.0148018841384 | 0.625 | MAP2K1 KSR1 BRAF RAF1 MAP2K2 | positive regulation of MAPK cascade |
| WP:WP2637 | 0.0148364293629 | 0.25 | MAP2K1 MAP2K2 | Structural Pathway of Interleukin 1 (IL-1) |
| HP:0100006 | 0.0152391607346 | 0.375 | BRAF RAF1 KRAS | Neoplasm of the central nervous system |
| HP:0000951 | 0.0157318045892 | 0.75 | MAP2K1 RAB3GAP1 BRAF KRAS MAP2K2 RAF1 | Abnormality of the skin |
| WP:WP195 | 0.0160767677044 | 0.25 | MAP2K1 MAP2K2 | IL-1 signaling pathway |
| HP:0001167 | 0.0162085838495 | 0.625 | MAP2K1 KRAS BRAF RAF1 RAB3GAP1 | Abnormality of finger |
| HP:0030178 | 0.0162884350978 | 0.5 | MAP2K1 KRAS BRAF MAP2K2 | Abnormality of central nervous system electrophysiology |
| GO:0031325 | 0.0168012607669 | 1.0 | MAP2K1 RAB3GAP1 BRAF KRAS RAF1 KSR1 ARAF MAP2K2 | positive regulation of cellular metabolic process |
| REAC:R-HSA-5654741 | 0.0168024726075 | 0.25 | BRAF KRAS | Signaling by FGFR3 |
| HP:0003808 | 0.0168652293303 | 0.75 | MAP2K1 RAB3GAP1 BRAF KRAS MAP2K2 RAF1 | Abnormal muscle tone |
| HP:0009115 | 0.0168915656744 | 0.625 | MAP2K1 KRAS BRAF RAF1 RAB3GAP1 | Aplasia/hypoplasia involving the skeleton |
| HP:0000431 | 0.017894477175 | 0.5 | RAB3GAP1 BRAF RAF1 KRAS | Wide nasal bridge |
| REAC:R-HSA-187687 | 0.0180422506392 | 0.25 | BRAF KRAS | Signalling to ERKs |
| HP:0000539 | 0.0182666998945 | 0.5 | MAP2K1 KRAS BRAF MAP2K2 | Abnormality of refraction |
| GO:0010604 | 0.0184377144721 | 1.0 | MAP2K1 RAB3GAP1 BRAF KRAS RAF1 KSR1 ARAF MAP2K2 | positive regulation of macromolecule metabolic process |
| GO:0006468 | 0.0188277130576 | 0.875 | MAP2K1 BRAF KRAS KSR1 MAP2K2 ARAF RAF1 | protein phosphorylation |
| HP:0030962 | 0.0190282767501 | 0.5 | MAP2K1 BRAF RAF1 KRAS | Abnormal morphology of the great vessels |
| GO:0045860 | 0.0191998051549 | 0.625 | MAP2K1 KSR1 BRAF RAF1 MAP2K2 | positive regulation of protein kinase activity |
| REAC:R-HSA-5654743 | 0.0193257881708 | 0.25 | BRAF KRAS | Signaling by FGFR4 |
| HP:0000534 | 0.0194177421944 | 0.5 | MAP2K1 KRAS BRAF MAP2K2 | Abnormal eyebrow morphology |
| HP:0002921 | 0.0198130668967 | 0.5 | MAP2K1 KRAS BRAF MAP2K2 | Abnormality of the cerebrospinal fluid |
| HP:0000153 | 0.0202197476364 | 0.75 | MAP2K1 RAB3GAP1 BRAF KRAS MAP2K2 RAF1 | Abnormality of the mouth |
| HP:0002167 | 0.0213605455935 | 0.625 | MAP2K1 KRAS BRAF RAF1 MAP2K2 | Neurological speech impairment |
| HP:0012758 | 0.0214525833514 | 0.75 | MAP2K1 RAB3GAP1 BRAF KRAS MAP2K2 RAF1 | Neurodevelopmental delay |
| HP:0011927 | 0.021879554628 | 0.5 | MAP2K1 BRAF RAF1 KRAS | Short digit |
| HP:0040064 | 0.0222539662917 | 0.75 | MAP2K1 RAB3GAP1 BRAF KRAS MAP2K2 RAF1 | Abnormality of limbs |
| HP:0000598 | 0.0224171545296 | 0.75 | MAP2K1 RAB3GAP1 BRAF KRAS MAP2K2 RAF1 | Abnormality of the ear |
| HP:0006519 | 0.0224977761754 | 0.25 | BRAF KRAS | Alveolar cell carcinoma |
| HP:0000492 | 0.0228302168248 | 0.625 | MAP2K1 KRAS BRAF RAF1 MAP2K2 | Abnormal eyelid morphology |
| GO:0004674 | 0.0232909099363 | 0.625 | ARAF MAP2K1 BRAF RAF1 MAP2K2 | protein serine/threonine kinase activity |
| HP:0004348 | 0.0234178973438 | 0.5 | MAP2K1 KRAS BRAF RAB3GAP1 | Abnormality of bone mineral density |
| HP:0000268 | 0.0242684914559 | 0.375 | BRAF RAF1 KRAS | Dolichocephaly |
| HP:0001713 | 0.0243320035336 | 0.5 | MAP2K1 KRAS BRAF MAP2K2 | Abnormal cardiac ventricle morphology |
| WP:WP3680 | 0.0245464965472 | 0.25 | MAP2K1 RAF1 | Association Between Physico-Chemical Features and Toxicity Associated Pathways |
| CORUM:5918 | 0.0248670854284 | 0.125 | KSR1 | KSR1 homo-oligomer complex |
| WP:WP3651 | 0.0253315062213 | 0.25 | MAP2K2 RAF1 | Pathways Affected in Adenoid Cystic Carcinoma |
| HP:0000929 | 0.0254359106874 | 0.75 | MAP2K1 RAB3GAP1 BRAF KRAS MAP2K2 RAF1 | Abnormal skull morphology |
| HP:0000179 | 0.0259546206912 | 0.375 | BRAF RAF1 KRAS | Thick lower lip vermilion |
| WP:WP2324 | 0.0261286537217 | 0.25 | MAP2K1 RAF1 | AGE/RAGE pathway |
| HP:0011025 | 0.026147316213 | 0.625 | MAP2K1 KRAS BRAF RAF1 MAP2K2 | Abnormal cardiovascular system physiology |
| REAC:R-HSA-5654736 | 0.0279439725577 | 0.25 | BRAF KRAS | Signaling by FGFR1 |
| HP:0100552 | 0.0282724469862 | 0.25 | BRAF KRAS | Neoplasm of the tracheobronchial system |
| HP:0000504 | 0.0286112512856 | 0.625 | RAB3GAP1 MAP2K1 KRAS BRAF MAP2K2 | Abnormality of vision |
| HP:0000175 | 0.0287750086045 | 0.5 | MAP2K1 KRAS BRAF MAP2K2 | Cleft palate |
| HP:0100737 | 0.0290381948062 | 0.5 | MAP2K1 KRAS BRAF MAP2K2 | Abnormal hard palate morphology |
| GO:0033674 | 0.0291592221593 | 0.625 | MAP2K1 KSR1 BRAF RAF1 MAP2K2 | positive regulation of kinase activity |
| HP:0004375 | 0.029554721474 | 0.375 | BRAF RAF1 KRAS | Neoplasm of the nervous system |
| HP:0001098 | 0.0303003299558 | 0.625 | RAB3GAP1 MAP2K1 KRAS BRAF MAP2K2 | Abnormal fundus morphology |
| HP:0004329 | 0.0307743122064 | 0.625 | RAB3GAP1 MAP2K1 KRAS BRAF MAP2K2 | Abnormal posterior eye segment morphology |
| HP:0100240 | 0.0308239670912 | 0.375 | BRAF RAF1 KRAS | Synostosis of joints |
| HP:0004404 | 0.0321285901864 | 0.375 | BRAF RAF1 KRAS | Abnormal nipple morphology |
| HP:0001311 | 0.0332028380473 | 0.5 | MAP2K1 KRAS BRAF MAP2K2 | Abnormal nervous system electrophysiology |
| GO:0009893 | 0.0356707076068 | 1.0 | MAP2K1 RAB3GAP1 BRAF KRAS RAF1 KSR1 ARAF MAP2K2 | positive regulation of metabolic process |
| HP:0012372 | 0.0360693442595 | 0.75 | MAP2K1 RAB3GAP1 BRAF KRAS MAP2K2 RAF1 | Abnormal eye morphology |
| HP:0007550 | 0.0362593331647 | 0.375 | MAP2K1 BRAF MAP2K2 | Hypohidrosis or hyperhidrosis |
| HP:0100491 | 0.0365252515147 | 0.5 | MAP2K1 KRAS BRAF MAP2K2 | Abnormality of lower limb joint |
| HP:0000248 | 0.0369800208504 | 0.375 | RAB3GAP1 BRAF RAF1 | Brachycephaly |
| GO:0043085 | 0.03767041438 | 0.75 | MAP2K1 RAB3GAP1 BRAF RAF1 KSR1 MAP2K2 | positive regulation of catalytic activity |
| HP:0000818 | 0.0388002641392 | 0.625 | MAP2K1 KRAS BRAF RAF1 RAB3GAP1 | Abnormality of the endocrine system |
| HP:0000202 | 0.0390909094316 | 0.5 | MAP2K1 KRAS BRAF MAP2K2 | Oral cleft |
| HPA:048040 | 0.0395991590065 | 1.0 | MAP2K1 RAB3GAP1 BRAF KRAS RAF1 KSR1 ARAF MAP2K2 | soft tissue 2; peripheral nerve |
| HP:0001871 | 0.0397629471445 | 0.625 | MAP2K1 KRAS BRAF RAF1 MAP2K2 | Abnormality of blood and blood-forming tissues |
| HP:0001627 | 0.040546506931 | 0.625 | MAP2K1 KRAS BRAF RAF1 MAP2K2 | Abnormal heart morphology |
| HP:0025276 | 0.0407250233681 | 0.375 | MAP2K1 BRAF MAP2K2 | Abnormality of skin adnexa physiology |
| HP:0004325 | 0.0407442770475 | 0.625 | RAB3GAP1 MAP2K1 KRAS BRAF MAP2K2 | Decreased body weight |
| HP:0012373 | 0.0411786056118 | 0.75 | MAP2K1 RAB3GAP1 BRAF KRAS MAP2K2 RAF1 | Abnormal eye physiology |
| HP:0011297 | 0.0421499585418 | 0.625 | MAP2K1 KRAS BRAF RAF1 RAB3GAP1 | Abnormal digit morphology |
| HP:0002818 | 0.0430873277361 | 0.375 | BRAF RAF1 KRAS | Abnormality of the radius |
| KEGG:04620 | 0.0433722245807 | 0.25 | MAP2K1 MAP2K2 | Toll-like receptor signaling pathway |
| KEGG:04666 | 0.0454007036402 | 0.25 | MAP2K1 RAF1 | Fc gamma R-mediated phagocytosis |
| HP:0011849 | 0.0468310960959 | 0.5 | MAP2K1 KRAS BRAF RAB3GAP1 | Abnormal bone ossification |
| HP:0011804 | 0.0470162564407 | 0.75 | MAP2K1 RAB3GAP1 BRAF KRAS MAP2K2 RAF1 | Abnormal muscle physiology |
| HP:0030669 | 0.0477075263813 | 0.625 | MAP2K1 KRAS BRAF RAF1 MAP2K2 | Abnormal ocular adnexa morphology |
| WP:WP75 | 0.0477902143581 | 0.25 | MAP2K1 MAP2K2 | Toll-like Receptor Signaling Pathway |
| HP:0005692 | 0.0489456009036 | 0.375 | BRAF RAF1 KRAS | Joint hyperflexibility |
| HP:0011314 | 0.0495146655034 | 0.5 | MAP2K1 KRAS BRAF MAP2K2 | Abnormality of long bone morphology |
| HP:0010989 | 0.0495208749973 | 0.25 | MAP2K1 BRAF | Abnormality of the intrinsic pathway |
| CORUM:5924 | 0.0497224828424 | 0.125 | RAF1 | RAF1-CNK1 complex, RAS stimulated |
| CORUM:5922 | 0.0497224828424 | 0.125 | RAF1 | RAF1-RAS complex, EGF induced |
| CORUM:5925 | 0.0497224828424 | 0.125 | BRAF | BRAF-CNK1 complex, not RAS stimulated |
| CORUM:7361 | 0.0497224828424 | 0.125 | ARAF | ARAF-PIK3R1 complex |
| HP:0001561 | 0.0498228947447 | 0.375 | BRAF RAF1 KRAS | Polyhydramnios |
Edges
| Protein 1 | Protein 2 | Score | Precision | Evidence |
|---|---|---|---|---|
| MAP2K1 | BRAF | 0.956 | 0.862 | hein_WMM bioplex (BRAF) bioplex_WMM boldt hein (MAP2K1) boldt_WMM |
| MAP2K1 | MAP2K2 | 0.843 | 0.788 | bioplex (MAP2K2) bioplex_WMM boldt youn_WMM gupta_WMM boldt_WMM treiber_WMM |
| BRAF | MAP2K2 | 0.598 | 0.668 | bioplex (BRAF) bioplex_WMM boldt boldt_WMM |
| BRAF | RAB3GAP1 | 0.32 | 0.511 | bioplex (BRAF) bioplex_WMM |
| BRAF | KRAS | 0.271 | 0.484 | bioplex (BRAF) bioplex_WMM |
| BRAF | RAF1 | 0.186 | 0.44 | hein_WMM bioplex (BRAF) bioplex_WMM boldt (RAF1) boldt_WMM |
| BRAF | ARAF | 0.184 | 0.437 | hein_WMM bioplex (BRAF) bioplex_WMM boldt boldt_WMM |
| CIRBP-AS1 | BRAF | 0.055 | 0.305 | bioplex (BRAF) bioplex_WMM boldt_WMM |
| MAP2K1 | KSR1 | 0.02 | 0.188 | hein_WMM hein (MAP2K1) |
| CIRBP-AS1 | MAP2K1 | 0.009 | 0.091 | bioplex_WMM WMM_only boldt_WMM |
| CIRBP-AS1 | MAP2K2 | 0.009 | 0.097 | bioplex_WMM WMM_only boldt_WMM |
| CIRBP-AS1 | KRAS | 0.008 | 0.091 | bioplex_WMM WMM_only |
| MAP2K1 | KRAS | 0.008 | 0.085 | bioplex_WMM WMM_only |
| MAP2K2 | KRAS | 0.008 | 0.068 | bioplex_WMM WMM_only |
| CIRBP-AS1 | RAB3GAP1 | 0.008 | 0.067 | bioplex_WMM WMM_only |
| MAP2K1 | RAB3GAP1 | 0.008 | 0.063 | bioplex_WMM youn_WMM gupta_WMM WMM_only |
| RAB3GAP1 | KRAS | 0.008 | 0.041 | bioplex_WMM WMM_only |
| ARAF | RAF1 | 0.008 | 0.041 | hein_WMM bioplex_WMM youn_WMM WMM_only |
| MAP2K2 | RAB3GAP1 | 0.008 | 0.029 | bioplex_WMM youn_WMM WMM_only |
| BRAF | KSR1 | 0.008 | 0.031 | hein_WMM boldt boldt_WMM |
| CIRBP-AS1 | RAF1 | 0.008 | 0.023 | bioplex_WMM WMM_only boldt_WMM |
| RAF1 | KSR1 | 0.008 | 0.026 | hein_WMM bioplex_WMM WMM_only |
| CIRBP-AS1 | ARAF | 0.007 | 0.007 | bioplex_WMM WMM_only |
| KRAS | ARAF | 0.007 | 0.005 | bioplex_WMM WMM_only |
| KRAS | RAF1 | 0.007 | 0.006 | bioplex_WMM WMM_only |
| ARAF | KSR1 | 0.007 | 0.004 | hein_WMM bioplex_WMM boldt boldt_WMM |
| RAB3GAP1 | ARAF | 0.007 | 0.004 | bioplex_WMM youn_WMM WMM_only |
| RAB3GAP1 | RAF1 | 0.007 | 0.003 | bioplex_WMM youn_WMM WMM_only |
| MAP2K1 | ARAF | 0.006 | 0.001 | hein_WMM bioplex_WMM youn_WMM hein (MAP2K1) |
| MAP2K2 | RAF1 | 0.005 | 0.011 | bioplex (MAP2K2) bioplex_WMM boldt (RAF1) youn_WMM boldt_WMM |
| MAP2K2 | ARAF | 0.005 | 0.009 | bioplex (MAP2K2) bioplex_WMM youn_WMM |
| MAP2K1 | RAF1 | 0.005 | 0.009 | hein_WMM bioplex_WMM boldt (RAF1) youn_WMM hein (MAP2K1) boldt_WMM |
Images
Click to enlarge
Complex HuMAP2_01070 has an average edge precision of 0.172 which is ranked 6508 out of all 6965 complexes.
Related Complexes
| Genename | Complexes |
|---|---|
| MAP2K2 | HuMAP2_01070 HuMAP2_03036 HuMAP2_04784 HuMAP2_04871 HuMAP2_06922 |
| ARAF | HuMAP2_01070 HuMAP2_04871 |
| MAP2K1 | HuMAP2_01070 HuMAP2_03036 HuMAP2_04487 HuMAP2_04871 |
| BRAF | HuMAP2_01070 HuMAP2_03036 HuMAP2_04871 |
| RAB3GAP1 | HuMAP2_01070 HuMAP2_01196 HuMAP2_03258 HuMAP2_05816 HuMAP2_05846 HuMAP2_06645 |
| KRAS | HuMAP2_01070 HuMAP2_03589 HuMAP2_04499 HuMAP2_05327 |
| RAF1 | HuMAP2_01070 HuMAP2_01698 HuMAP2_04211 HuMAP2_04871 |
| KSR1 | HuMAP2_01070 HuMAP2_04487 |
| CIRBP-AS1 | HuMAP2_01070 HuMAP2_04871 |